



Title	False Hypercortisolemia Due to Abnormal Albumin-Cortisol Binding in a Patient with Familial Dysalbuminemic Hyperthyroxinemia
Author(s)	Chiba, Koki; Kameda, Hiraku; Miya, Aika; Nomoto, Hiroshi; Cho, Kyu Yong; Nakamura, Akinobu; Jin, Shigeki; Matoba, Kotaro; Miyoshi, Hideaki; Atsumi, Tatsuya
Citation	Thyroid, 32(2), 219-220 <a href="https://doi.org/10.1089/thy.2021.0460">https://doi.org/10.1089/thy.2021.0460</a>
Issue Date	2022-02-10
Doc URL	<a href="http://hdl.handle.net/2115/88118">http://hdl.handle.net/2115/88118</a>
Rights	Final publication is available from Mary Ann Liebert, Inc., publishers <a href="http://dx.doi.org/10.1089/thy.2021.0460">http://dx.doi.org/10.1089/thy.2021.0460</a>
Type	article (author version)
File Information	thy.2021.0460.pdf



[Instructions for use](#)

**Letter to the Editor**

**False hypercortisolemia due to abnormal albumin-cortisol binding in a patient with familial dysalbuminemic hyperthyroxinemia**

**Running title:** Hypercortisolemia with FDH

**Key words:** hypercortisolemia, hyperthyroxinemia, albumin

**Authors:**

Koki Chiba, M.D.<sup>1)</sup>, Hiraku Kameda, M.D., Ph.D.<sup>1)</sup>, Aika Miya, M.D., Ph.D.<sup>1)</sup>, Hiroshi Nomoto, M.D., Ph.D.<sup>1)</sup>, Kyu Yong Cho, M.D., Ph.D.<sup>1)</sup>, Akinobu Nakamura, M.D., Ph.D.<sup>1)</sup>, Shigeki Jin, Ph.D.<sup>2)</sup>, Kotaro Matoba, M.D., Ph.D.<sup>2)</sup>, Hideaki Miyoshi, M.D., Ph.D.<sup>1,3)</sup>, Tatsuya Atsumi, M.D., Ph.D.<sup>1)</sup>

<sup>1</sup>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

<sup>2</sup>Department of Forensic Medicine, Graduate School of Medicine, Sapporo, Hokkaido University, Japan.

<sup>3</sup>Division of Diabetes and Obesity, Faculty of Medicine and Graduate School of Medicine,

19 Hokkaido University, Sapporo, Japan.

20

21 **Author for correspondence:** Hiraku Kameda, M.D., Ph.D.

22 Department of Rheumatology, Endocrinology and Nephrology,

23 Faculty of Medicine and Graduate School of Medicine,

24 Hokkaido University Graduate School of Medicine

25

26 **Contact information**

27 Koki Chiba, ko.chiba419@gmail.com, +81-011-706-5915

28 Hiraku Kameda, hirarak@gmail.com, +81-011-706-5915

29 Aika Miya, miyaxgag@gmail.com, +81-090-6874-0078

30 Hiroshi Nomoto, hnomoto@med.hokudai.ac.jp, +81-090-3117-4775

31 Kyu Yong Cho, ky9494@gmail.com, +81-090-6266-4785

32 Akinobu Nakamura, akinbo@huhp.hokudai.ac.jp, +81-090-7654-6586

33 Shigeki Jin, s-jin@hs.hokudai.ac.jp, +81-011-706-5905

34 Kotaro Matoba, k-matoba@med.hokudai.ac.jp, +81-011-706-5905

35 Hideaki Miyoshi, hidemiyoshi2003@yahoo.co.jp, +81-011-706-8192

36 Tatsuya Atsumi, at3tat@med.hokudai.ac.jp, +81-011-706-5913

37

38 **Dear Editor,**

39 The report of familial dysalbuminemic hyperthyroxinemia (FDH) due to Pro<sup>218</sup> (R218P)  
40 mutant albumin that caused hypercortisolemia in Swiss family members by Moran et al.  
41 (1) was of great interest to us. FDH subjects with R218P have been reported in Swiss  
42 and Japanese families (2)(3), and here, we report to our knowledge the first Japanese  
43 FDH case of false hypercortisolemia.

44 A 46-year man, previously diagnosed with FDH due to R218P (TSH 2.2 mU/L, FT3 8.2  
45 pmol/L, FT4 >103.0 pmol/L) by genetic testing (3), developed hypercortisolemia with  
46 normal adrenocorticotrophic hormone (ACTH) level (ACTH 14.2 pmol/L, cortisol 957.3  
47 nmol/L) during an investigation for Parkinson's syndrome and was referred to our  
48 department for further examination. His cortisol level was 195.9 nmol/L at midnight and  
49 411.1 nmol/L after a low dose dexamethasone overnight test. ACTH and cortisol  
50 responded to CRH load, although basal and peak cortisol levels were high (976.6 and  
51 1487.0 nmol/L, respectively). A high dose dexamethasone overnight test showed  
52 suppressed ACTH and cortisol levels, and MRI showed no obvious pituitary adenoma.  
53 Despite a significantly high cortisol level, no Cushing signs or metabolic abnormalities  
54 were observed and urinary free cortisol was within the normal range (30.7 µg/day),

suggesting the presence of factors affecting the laboratory testing. We removed albumin from the patient serum using an immunoprecipitation method (Pierce Direct Magnetic IP/Co-IP Kit; Thermo Fisher Scientific, Waltham, MA, USA) and anti-albumin antibody (Proteintech, Rosemont, IL, USA). Cortisol levels were measured by LC-MS/MS performed using a Dionex Ultimate 3000 liquid chromatography system coupled to a TSQ Quantum Access Max triple stage quadrupole mass spectrometer containing a heated-electrospray ionization (HESI-II) probe (Thermo Fisher Scientific).

His serum cortisol decreased by 38% after removing albumin despite unremarkable changes in the controls such as ectopic ACTH syndrome, primary hyperparathyroidism and resistance to thyroid hormone beta (Table 1), suggesting the binding rate of cortisol to mutant albumin in the patient was increased, leading to false hypercortisolemia.

R218P causes a missense mutation (G to C) of the same nucleotide, which leads to the replacement of normal Arg218 with a proline. This mutation results in the presence of a restriction site for *Ava*II (4). The presence of R218P is characterized by extremely high concentrations of total T4 compared with other FDH types. Regarding cases of R218P, moderate conformational changes are combined with a concomitant distortion of the helix main chain, which promotes the translation of T4 toward the mutated residue. This closer contact results in very strong T4 binding (5).

In our patient, the binding rate of cortisol to mutant albumin might be increased, leading to false hypercortisolemia, and the degree of cortisol reduction after albumin removal was similar to that of the Swiss case. Our case highlights Japanese individuals with FDH due to R218P mutant albumin develop hypercortisolemia, confirming the results of the Swiss case. More detailed molecular studies on cortisol binding to albumin are required.

## **Acknowledgments**

We thank J. Ludovic Croxford, PhD, from Edanz (<https://jp.edanz.com/ac>) for editing a draft of this manuscript.

## **Author Contribution statement**

Koki Chiba and Hiraku Kameda wrote the manuscript. Shigeki Jin and Kotaro Matoba measured cortisol levels. All authors critically revised the report, commented on drafts of the manuscript, and approved the final report.

## **Author Disclosure Statement**

The authors have nothing to disclose.

91

92   **Funding statement**

93   There is no funding information to declare.

94   **References**

- 95   1.       Moran C, Seger C, Taylor K, Oddy S, Burling K, Rajanayagam O, et al.  
96   Hyperthyroxinemia and Hypercortisolemia due to Familial Dysalbuminemia. *Thyroid*.  
97   2020;30(11):1681-4.
- 98   2.       Pannain S, Feldman M, Eiholzer U, Weiss RE, Scherberg NH, Refetoff S.  
99   Familial dysalbuminemic hyperthyroxinemia in a Swiss family caused by a mutant  
100   albumin (R218P) shows an apparent discrepancy between serum concentration and  
101   affinity for thyroxine. *J Clin Endocrinol Metab*. 2000;85(8):2786-92.
- 102   3.       Wada N, Chiba H, Shimizu C, Kijima H, Kubo M, Koike T. A novel missense  
103   mutation in codon 218 of the albumin gene in a distinct phenotype of familial  
104   dysalbuminemic hyperthyroxinemia in a Japanese kindred. *J Clin Endocrinol Metab*.  
105   1997;82(10):3246-50.
- 106   4.       Hoshikawa S, Mori K, Kaise N, Nakagawa Y, Ito S, Yoshida K. Artificially  
107   elevated serum-free thyroxine levels measured by equilibrium dialysis in a pregnant  
108   woman with familial dysalbuminemic hyperthyroxinemia. *Thyroid*. 2004;14(2):155-60.
- 109   5.       Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, et al.  
110   Structural basis of albumin-thyroxine interactions and familial dysalbuminemic  
111   hyperthyroxinemia. *Proc Natl Acad Sci U S A*. 2003;100(11):6440-5.

112

113

**Table 1. Cortisol levels after pre/post albumin removal.**

Case	Pre-cortisol (nmol/L)	Post-cortisol (nmol/L)	% Change
This study	1117.3	692.5	−38.0
Control 1	1131.1	1087.0	−4.0
Control 2	168.3	231.7	38.7
Control 3	63.5	69.0	8.2

Pre-cortisol: amount of cortisol before removing albumin. Post-cortisol: amount of cortisol measured by LC-MS/MS after removing albumin by immunoprecipitation using an anti-albumin antibody. % Change: percentage change in cortisol before and after albumin removal. Control 1: ectopic ACTH syndrome. Control 2: primary hyperparathyroidism. Control 3: resistance to thyroid hormone beta.